“
TL;DR
This is a protocol for a double-blind, randomised controlled, non-inferiority trial comparing amber photobiomodulation (590 nm) with liposomal tranexamic acid for treating melasma in 54 women.
BMJ Open · 4 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This is a protocol for a double-blind, randomised controlled, non-inferiority trial comparing amber photobiomodulation (590 nm) with liposomal tranexamic acid for treating melasma in 54 women.
The study is a planned, double-blind, randomised, controlled, non-inferiority trial to evaluate amber photobiomodulation (590 nm) versus liposomal tranexamic acid for melasma in 54 eligible women. The primary outcome is the change in MASI score at week 12. Assessments are at weeks 0, 6, 12, and follow-ups at 16 and 20 weeks. This protocol paper does not report results; it describes a future trial. A key limitation noted is the potential for variability in replicating the precise light parameters across different devices.